Quantitative Clinical Pharmacology of T‐Cell Engaging Bispecifics: Current Perspectives and Opportunities
T‐cell directing/engaging bispecifics (TDBs) enable a powerful mode of action by activating T‐cells through the creation of artificial immune synapses. Their pharmacological response involves the dynamic inter‐relationships among T‐cells, tumor cells, and TDBs. This results in complex and challengin...
Saved in:
Main Authors: | Peter N. Morcos (Author), Junyi Li (Author), Iraj Hosseini (Author), Chi‐Chung Li (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2021-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer
by: Tian Huan, et al.
Published: (2023) -
The landscape of bispecific T cell engager in cancer treatment
by: Shujie Zhou, et al.
Published: (2021) -
A Modeling Framework to Characterize Cytokine Release upon T‐Cell-Engaging Bispecific Antibody Treatment: Methodology and Opportunities
by: Xiaoying Chen, et al.
Published: (2019) -
Quantitative Systems Pharmacology for Neuroscience Drug Discovery and Development: Current Status, Opportunities, and Challenges
by: Hugo Geerts, et al.
Published: (2020) -
Manufacturability and functionality assessment of different formats of T-cell engaging bispecific antibodies
by: Han Ping Loh, et al.
Published: (2023)